As of today (2022-08-07), United Therapeutics's share price is $221.65. United Therapeutics's Tangible Book per Share of Jun. 2022 for the quarter that ended in Jun. 2022 was $93.95. Hence, United Therapeutics's Price to Tangible Book Ratio of today is 2.36.
The historical rank and industry rank for United Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
UTHR'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16 Med: 3.14 Max: 18.16
Current: 2.36
During the past 13 years, United Therapeutics's highest Price to Tangible Book Ratio was 18.16. The lowest was 1.16. And the median was 3.14.
UTHR's Price-to-Tangible-Book is ranked better than 56.09% of 1346
companies
in the Biotechnology industry
Industry Median: 2.74
vs UTHR: 2.36
A closely related ratio is called PB Ratio. As of today, United Therapeutics's share price is $221.65. United Therapeutics's Book Value per Sharefor the quarter that ended in Jun. 2022 was $94.93. Hence, United Therapeutics's P/B Ratio of today is 2.33.
United Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for United Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
United Therapeutics Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Price-to-Tangible-Book
3.11
1.81
1.47
2.09
2.49
United Therapeutics Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Price-to-Tangible-Book
2.24
2.20
2.49
1.97
2.51
Competitive Comparison
For the Biotechnology subindustry, United Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, United Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Price-to-Tangible-Book falls into.
United Therapeutics Price-to-Tangible-Book Calculation
United Therapeutics's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
United Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of United Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.3(0.14%) Volume: 329,369 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:UTHR has been successfully added to your 
